PubMed | d Republican Institute of Reproductive Health, b Gynuity Health Projects, a Gynuity Health Projects and Yerevan State Medical University
Type: | Journal: The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception | Year: 2016
The aim of the study was to assess the efficacy and acceptability of a regimen using mifepristone and buccal misoprostol with unlimited dosing for second trimester abortion in Armenia.Women seeking to terminate 13-22 week pregnancies were enrolled in the study. Participants swallowed 200mg mifepristone in the clinic and were instructed to return to the hospital for induction 24-48h later. During induction, women were given 400g buccal misoprostol every 3h until the fetus and placenta were expelled. The abortion was considered a success if complete uterine evacuation was achieved without oxytocin or surgery.A total of 120 women with a median gestational age of 18 weeks participated in the study. All women began misoprostol induction around 24h after taking mifepristone. Complete uterine evacuation was achieved in 119 (99.2%) women. The median induction-to-abortion interval was 10.3h (range 4-17.4) with a mean of 9.52.5h. A median of four misoprostol doses (range 2-6) with a mean of 41 misoprostol doses were administered. The induction-to-abortion interval, number of misoprostol doses, pain score and analgesia use increased as gestational age advanced. Acceptability of the method was high among both patients and providers.The medical abortion regimen of 200mg mifepristone followed 24h later by induction with 400g buccal misoprostol administered every 3h, with no limit on the number of doses used for the termination of pregnancies of 13-22 weeks gestation is an effective and acceptable option for women.
PubMed | b Gynuity Health Projects, Tbilisi State Medical University and a Gynuity Health Projects
Type: Journal Article | Journal: The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception | Year: 2016
The aim of the study was to examine the acceptability and feasibility of early medical abortion using 200mg mifepristone and 400g buccal misoprostol in Georgia, outside the capital city of Tbilisi.A total of 622 women in four regions of western and eastern Georgia who presented for termination of pregnancy at up to 63d of gestation were enrolled in the study. In the western regions, women took one 200mg pill of mifepristone in the clinic and were given the option of administering 400g misoprostol buccally, either at the clinic or at home, 24-48h later. In the eastern region, women were given the option to take both drugs at home. Abortion status was determined 2 weeks after mifepristone administration.Ninety-five percent of participants had a successful abortion. Twenty-one percent of women in the eastern region elected to take mifepristone at home; nearly all participants in both regions (98%) chose to take misoprostol at home. Ninety-five percent of women were very satisfied or satisfied with the method, and 95% said they would prefer medical abortion for a future procedure.Medical abortion with mifepristone and 400g buccal misoprostol is an acceptable and feasible option for women in Georgia, outside the capital city of Tbilisi.